SIGA Technologies Inc. (SIGA)

NASDAQ: SIGA · IEX Real-Time Price · USD
12.40
3.75 (43.35%)
At close: May 20, 2022 4:00 PM
15.33
2.93 (23.63%)
After-hours:May 20, 2022 7:59 PM EDT
Market Cap897.84M
Revenue (ttm)139.40M
Net Income (ttm)69.90M
Shares Out72.41M
EPS (ttm)0.91
PE Ratio13.67
Forward PE11.05
Dividend$0.45 (3.63%)
Ex-Dividend DateMay 16, 2022
Volume81,645,396
Open9.11
Previous Close8.65
Day's Range8.85 - 12.47
52-Week Range5.66 - 12.47
Beta0.49
Analystsn/a
Price Targetn/a
Earnings DateMay 5, 2022

About SIGA

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

IndustryPharmaceuticals
IPO DateSep 9, 1997
Employees39
Stock ExchangeNASDAQ
Ticker SymbolSIGA
Full Company Profile

Financial Performance

In 2021, SIGA's revenue was $133.67 million, an increase of 6.97% compared to the previous year's $124.96 million. Earnings were $69.45 million, an increase of 23.27%.

Financial Statements

News

6 Stocks To Watch Amid Monkeypox Outbreak

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?

Other symbols:CMRXEBSINOTNXP
17 hours ago - Benzinga

Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, Treatments

Monkeypox stocks SIGA, EBS and TNXP are all advancing as fears mount over monkeypox. The disease is related to smallpox.

Other symbols:EBSTNXP
23 hours ago - InvestorPlace

Monkeypox Fears Drive Smallpox Antiviral Makers Higher

Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.

Other symbols:CMRXEBS
1 day ago - Zacks Investment Research

Why SIGA Technologies Shares Are Trading Higher Today?

The FDA approved the intravenous (IV) formulation of SIGA Technologies Inc's (NASDAQ: SIGA) TPOXX for smallpox. The oral formulation of TPOXX (tecovirimat) is approved in the US, Canada, and Europe to t...

1 day ago - Benzinga

Why These 2 Nasdaq Stocks Soared Thursday

The tech-heavy index held up better than the rest of the market.

Other symbols:GRAB
1 day ago - The Motley Fool

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

- FDA approval provides an important option for those unable to take oral formulation of TPOXX - - FDA approval provides an important option for those unable to take oral formulation of TPOXX -

2 days ago - GlobeNewsWire

New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TP...

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. D...

1 week ago - GlobeNewsWire

SIGA Reports Financial Results for Three Months Ended March 31, 2022

- First Sale of Intravenous (IV) TPOXX® to U.S. Government under the 19C BARDA Contract –

2 weeks ago - GlobeNewsWire

SIGA Declares Special Dividend of $0.45 Per Share

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special divide...

2 weeks ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Res...

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference ...

3 weeks ago - GlobeNewsWire

3 Biotech Stocks Under $10 to Add to Your Buy List

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on In...

Other symbols:ABCLOVID
3 weeks ago - InvestorPlace

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021

- Approximately $113 Million of U.S. Product Sales in 2021 –

2 months ago - GlobeNewsWire

SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has i...

2 months ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference c...

2 months ago - GlobeNewsWire

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

Investigating TPOXX® in Combination with Bioarchitech's Oncolytic Vaccinia Immunotherapy Platform Investigating TPOXX® in Combination with Bioarchitech's Oncolytic Vaccinia Immunotherapy Platform

3 months ago - GlobeNewsWire

SIGA Technologies to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference from January 25-...

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it will b...

4 months ago - GlobeNewsWire

SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat

Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications

4 months ago - GlobeNewsWire

Siga Technologies Inc. (SIGA) Upgraded to Buy: What Does It Mean for the Stock?

Siga Technologies Inc. (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Health Ca...

5 months ago - GlobeNewsWire

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat

- Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications -

6 months ago - GlobeNewsWire

SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021

- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter -

6 months ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financi...

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference c...

6 months ago - GlobeNewsWire

SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®

NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its 75A5...

8 months ago - GlobeNewsWire

SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company's Chief Executive ...

8 months ago - GlobeNewsWire

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021

- Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter –

9 months ago - GlobeNewsWire